Phosphorus(V) Drug Conjugates Balancing Drug Loading and Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates like Brentuximab vedotin face limitations in the number of drug molecules that can be attached to the antibody, leading to challenges in pharmaceutical applications.
Innovation Solution
Development of conjugates with a receptor binding molecule linked to a drug moiety through a linker, utilizing polyalkylene glycol units and varying linker lengths to enhance drug loading and stability, allowing for a range of drug molecules to be attached, from 1 to 10 for formula (I) and 1 to 20 for formula (II).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the number of drug molecules attached to the antibody is increased, then the antitumor activity is improved, but the antigen-independent toxicity increases
Solution Approach 1:
The patent applies parameter changes by modifying the linker structure (introducing PEG substituents, varying linker lengths) and drug loading parameters to achieve optimal balance between antitumor activity and toxicity. The conjugates are designed with specific drug-to-antibody ratios (DAR 1-10) and optimized linker configurations to maximize therapeutic index
Solution Approach 2:
The patent uses composite materials by creating antibody-drug conjugates with specific composite structures combining antibody molecules, linker compounds, and drug payloads in controlled ratios. The conjugates comprise multiple components (RBM, linker, drug moiety) arranged in specific configurations to achieve desired pharmacological properties
2Stability of the object's composition
If the linker structure is modified to improve stability, then the conjugate stability is improved, but the manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the linker structure into distinct functional segments: the original linker compound and attached PEG substituent units. This allows independent optimization of each segment's properties while maintaining overall conjugate stability and facilitating manufacturing
3Duration of action of moving object
If polyethylene glycol substituents are introduced to reduce hydrophobicity, then the pharmacokinetics are improved, but the device complexity increases
Solution Approach 1:
The patent uses PEG substituents as intermediary elements between the antibody and drug payload, acting as hydrophilic spacers that reduce overall conjugate hydrophobicity. These intermediary PEG units improve pharmacokinetic properties by reducing non-specific clearance while maintaining the essential drug-binding function
Data Source
AI summary
The present invention relates to a conjugate having the formula (I):wherein a receptor binding molecule (RBM) is connected with a drug moiety (D). The present invention also relates to intermediates for producing the same, methods of preparing the same, pharmaceutical compositions comprising the same, as well as uses thereof.